BREAKING: Futures Loom With Tesla, Jobs And Possible Gov't Shutdown AheadBridgeBio Pharma (BBIO) said Sunday its heart-disease drug, Attruby, cut the risk of death almost in half in an exploratory study that one cardiologist says could be a game-changer for the disease.Attruby is approved to treat patients with cardiomyopathy due to transthyretin amyloidosis. In this condition, abnormal plaque called amyloid builds up on the heart, causing damage. Patients who took Attruby for 30 months had a 49% lower risk ...

- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p<0.0001) - The difference in cumulative events increased progressively with results at Month 30 showing 53 events were avoided per 100 treated participants (95% CI:29–79) PALO ALTO, Calif., Sept. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“Bridge ...

PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clinical trials oral presentation, one oral presentation, and three poster sessions will be shared at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2025, taking place in Minneapolis, MN from September 26 - 29, 2025. Late Breaking Clinical Trials Oral ...

Investors in BridgeBio Pharma Inc (Symbol: BBIO) saw new options become available this week, for the May 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel , our YieldBoost formula has looked ...

嘉信1000指数ETF目标价分析 - 基于其底层持仓成分股的分析师平均目标价计算 该ETF的隐含目标价为每股35.10美元[1] - 该ETF近期交易价格接近每股31.75美元 意味着分析师认为其存在10.55%的上涨空间[2] 具有显著上涨潜力的成分股 - QXO公司近期股价为每股20.77美元 分析师平均目标价为33.73美元 隐含62.38%的上涨空间[2] - SPS Commerce近期股价为每股105.53美元 分析师平均目标价为157.54美元 隐含49.29%的上涨空间[2] - BridgeBio Pharma近期股价为每股51.21美元 分析师平均目标价为64.67美元 隐含26.28%的上涨空间[2] 目标价有效性探讨 - 分析师目标价可能反映对未来乐观预期 也可能是基于过时信息的滞后指标[3] - 目标价大幅高于当前股价可能成为未来下调目标价的前兆[3] - 目标价合理性需结合公司最新发展和行业动态进行进一步评估[3]

市场竞争格局 - BridgeBio Pharma与辉瑞、Alnylam在ATTR心肌病治疗领域展开直接竞争 声称其药物疗效更优且成本更低[1] - 辉瑞药物Vyndamax被宣传为"首款且唯一获批疗法" 但刻意隐瞒BridgeBio药物已于2024年11月上市及Alnylam药物自今年3月投入使用的事实[1] - 分析师预测辉瑞Vyndamax今年营收约66亿美元 Alnylam药物Amvuttra到2030年年营收预计达60亿美元 BridgeBio药物Attruby今年销售额将突破3亿美元 2030年有望达21亿美元[2][3] 产品疗效主张 - BridgeBio称其药物Attruby是唯一能实现TTR蛋白"近乎完全稳定"的药物 该疗效主张经FDA批准纳入正式说明书[3] - 辉瑞在宣传材料中同样宣称"实现TTR蛋白的近乎完全稳定" 但该表述未出现在FDA批准的正式说明书中[3] - Alnylam在《新英格兰医学杂志》论文中展示经调整的数据显示18个月生存获益 但未调整数据显示其药物直到第30个月才显现生存获益 而BridgeBio药物在第20个月已展现生存获益[6] 营销推广争议 - 辉瑞被指控采用不公平对比方式 被比喻为"拿跑步状态最好的一天与状态最差的一天做对比"而非基于平均水平[1] - 制药行业存在采用可能被视为误导性方式推广产品的现象 通常会在宣传内容旁以较小字体附上免责声明[4] - 医学会议是制药公司推广产品的"高风险高回报场所" 因为处方医生大多出席此类会议[5] 监管环境现状 - FDA下属处方药推广办公室(OPDP)负责监管药品广告 但今年大规模裁员导致人员大幅缩减[5] - OPDP通常是在竞争对手或医生投诉后才会知晓问题推广行为 每年仅能处理少量投诉[5] - BridgeBio已就辉瑞的推广行为向OPDP提交信函 但尚未看到该机构采取行动[5] 行业专家观点 - 辉瑞回应称视频属于误播 并强调所有教育材料均严格依据FDA规定制定[2][3] - Alnylam研发负责人称BridgeBio对论文数据的质疑是"小题大做" 强调公司致力于透明度[7] - 行业专家指出多数制药企业会设立内部审核团队以避免存在法律或监管风险的宣传主张[4]

公司产品与研发 - 公司正在开发用于治疗常染色体显性遗传性低钙血症1型(ADH1)的小分子药物encaleret [2] - 公司首席医疗官将详细介绍encaleret临床开发项目 [3] - 公司通过患者案例视频展示ADH1患者体验 [4] 行业专家参与 - 美国国立卫生研究院NIDCR高级研究医师将介绍ADH1疾病和encaleret药物概述 [3] - 行业专家团队包括临床开发专家和科研机构研究人员 [3] 活动安排 - 本次投资者网络研讨会包含主题介绍、临床项目评审和市场机会展望 [2][3][4] - 活动最后设有问答环节 [4]

公司研发进展 - 公司正在开发用于治疗常染色体显性低钙血症1型(ADH1)的小分子药物encaleret [2] - 临床开发项目由Calcilytix Therapeutics公司首席医疗官Scott Adler博士负责 [3] - Calcilytix Therapeutics是BridgeBio的关联公司 专门致力于encaleret的开发 [3] 专业团队组成 - 美国国立卫生研究院NIDCR高级研究医师Rachel Gafni博士参与介绍ADH1和encaleret概述 [3] - 公司团队包括医学专家和研究分析师共同参与本次投资者网络研讨会 [3] 会议内容安排 - 会议包含ADH1市场机会展望 [4] - 通过患者Jessica的视频资料展示ADH1患者的真实经历 [4] - 会议最后设有问答环节 [4]

BridgeBio Pharma (NasdaqGS:BBIO) Update / Briefing September 10, 2025 08:00 AM ET Company ParticipantsAnanth Sridhar - COORachel Gafni - Senior Research PhysicianScott Adler - Chief Medical OfficerBenet Pera Gresely - Senior Associate - Biotech Equity ResearchJosh Schimmer - Managing DirectorRyan Mcelroy - Equity Research AssociateAdhirath S - Vice PresidentAndrew Tsai - SVPDanielle Brill - Managing DirectorAnupam Rama - Executive Director - Biotechnology Equity ResearchConference Call ParticipantsTyler Van ...

Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar September 10, 2025 Encaleret is an investigational drug. Its safety and efficacy have not been fully evaluated by any regulatory authority. Alexis and Jackson Living with ADH1 Forward-Looking Statements and Disclaimer Statements in this Presentation that are not statements of historical fact are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exc ...